Brief: Prostatype Genomics H2 EBITDA Loss Widens To SEK 20.44 Mln

Prostatype Genomics AB

13/02/2025 15:34

Feb 13 (Reuters) - Prostatype Genomics AB  PROGEN.ST :
    * H2 NET SALES AMOUNTED TO 84 TSEK* (908)
    * H2 EBITDA -20,437 TSEK (-17,797)
    * MARKET ENTRY, MEDICARE APPROVAL FOR REIMBURSEMENT OF
PROSTATYPE
TEST, STRONG, SCIENTIFICALLY PROVEN PERFORMANCE NEEDED
FORSIGNIFICANT SALES REVENUE IN U.S.

Source text:  ID:nMFN2rPbM4 
Further company coverage:  PROGEN.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))